Study of IMCY-0098 in Patients With Recent Onset Type 1 Diabetes
Status:
Completed
Trial end date:
2019-08-30
Target enrollment:
Participant gender:
Summary
This clinical study will evaluate the safety of an innovative approach expected to be
disease-modifying by stopping the auto-immune-mediated destruction of islet β-cells in the
pancreas. Three doses of the investigational product will be tested in successive cohorts.
Although safety is the first objective of this study, we will gather efficacy data and
perform a set of immunological tests to further understand the mechanism of action of this
new approach in young adults with recent onset type 1 diabetes.